You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Adam covers proteomics and life science mass spectrometry for GenomeWeb.
While some commentators have blamed FDA, many test developers say the agency hasn't been an issue and that, in fact, they are making speedy progress.
Lab firms are acquiring equipment and implementing approaches like pooled testing, but it remains unclear if this will be enough to meet a fall surge.
Washington University researchers and a team including scientists from Eli Lilly independently identified a modified form of tau as a promising Alzheimer's marker.
The coming uptick in flu and other respiratory viruses will likely complicate the diagnosis of COVID-19 even as labs continue to struggle with capacity.
Labs and airports are collaborating to offer SARS-CoV-2 testing with many countries requiring passengers show a negative result to enter or avoid quarantine.
The facility, which plans to launch an MRM assay for HER2 as its initial test, is one of the few clinical labs to focus primarily on targeted protein mass spec.
Even as the broader lab industry struggles to meet SARS-CoV-2 testing needs, many labs focused on nursing homes are unable to benefit from the demand.
Last month the agency said it had begun examining Medicare claims data to look for potential fraud in ordering of SARS-CoV-2 testing and related tests.
The researchers found that levels of the marker, which has also been studied in diseases like MS and Alzheimer's, correlated with severity of traumatic brain injury.
Sciex has discontinued the Topaz platform three years after its launch while Thermo Fisher aims to drive adoption of its Cascadion following a recent US launch.